Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563212 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis
A Phase 1 study of Pulmonary Fibrosis, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00563212 is a Phase 1 study of Pulmonary Fibrosis that has completed, run by NYU Langone Health. The registered enrollment target is 12 participants, below the 888-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00563212, a Phase 1 study of Pulmonary Fibrosis, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Idiopathic pulmonary fibrosis (IPF) is a progressive disease for which there is no effective treatment. Interferon-gamma is a medication that has been used for other lung diseases to decrease scarring and fibrosis. Studies of interferon-gamma injected under the skin did not show any improvement in survival in patients with IPF. We hypothesize that giving interferon-gamma as a nebulized mist directly into the lungs can affect the immune system in a way that decreases fibrosis.
Conditions Studied
Interventions
- DRUG aerosol interferon-gamma
Study Locations (1)
New York
- Division of Pulmonary & Critical Care Medicine, NYU School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-01 |
| Est. Completion | 2018-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00563212
The ClinicalTrials.gov registry entry for NCT00563212 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 888-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (99% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which aerosol interferon-gamma is the first listed.
NCT00563212 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00563212 about?
NCT00563212 is a clinical study titled "A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis". Idiopathic pulmonary fibrosis (IPF) is a progressive disease for which there is no effective treatment. Interferon-gamma is a medication that has been used for other lung diseases to decrease scarring and fibrosis. Studies of interferon-gamma injected under the skin did not show any improvement in s...
What is the current status of trial NCT00563212?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2007-01. Estimated completion is 2018-12-01.
What conditions does trial NCT00563212 study?
This clinical trial studies the following conditions: Pulmonary Fibrosis.
What interventions are being tested in trial NCT00563212?
The interventions under investigation include: aerosol interferon-gamma (DRUG).
Who is sponsoring clinical trial NCT00563212?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00563212 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
RECRUITING · Phase 1
-
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
COMPLETED · Phase 1
-
Advanced Imaging for Pulmonary Fibrosis
RECRUITING · Phase 2
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
-
FAPI PET for Lung Fibrosis
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.